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We explored the impact of coronavirus virus 2019 (COVID-19) pandemic on pa-
tients with Dravet syndrome (DS) and their family. With European patient advo-
cacy groups (PAGs), we developed an online survey in 10 languages to question 
health status, behavior, personal protection, and health services before and after lock-
down. Approximately 538 European PAG members received electronic invitations. 
Survey ran from April 14, to May 17, 2020, with 219 answers; median age 9 year 
10 months. Protection against infection was highly used prior to COVID-19, but 88% 
added facemask-use according to pandemic recommendations. Only one patient was 
tested positive for COVID-19. Most had stable epilepsy during lockdown, and few 
families (4%) needed emergency care during lockdown. However, behavior disorder 
worsened in over one-third of patients, regardless of epilepsy changes. Half of ap-
pointments scheduled prior to lockdown were postponed; 12 patients (11%) had ap-
pointments fulfilled; and 39 (36%) had remote consultations. Responders welcomed 
remote consultations. Half of responders were unsatisfied with psychological remote 
support as only few (21 families) received this support. None of the five of patient in 
clinical trials stopped investigational treatment. Prior adoption of protective meas-
ures against general infection might have contributed to avoiding COVID-19 infec-
tions. Protocols for the favored remote contact ought to now be prepared.
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1 |  INTRODUCTION
Dravet syndrome (DS) is characterized by febrile or afebrile 
seizures starting in the first year of life and often evolves to 
status epilepticus.1,2 Over 80% of patients carry a loss-of-
function mutation in the SCN1A gene. 1. With incidence be-
tween 1/16 000 and 1/40 000 infants,3–6 DS is rare and only 
represents about 3 to 7% of cases with infantile epilepsy. 
During the second year of life, patients might experience 
various seizure types, cognitive plateauing, motor dysfunc-
tion, and behavioral problems.1,2 Premature death occurs in 
10%–15% of patients, with half being sudden unexplained 
death in epilepsy (SUDEP).7
Seizure recurrence makes patients with DS and their fam-
ilies a vulnerable population when healthcare systems are 
compromised, such as has arisen during the coronavirus dis-
ease 2019 (COVID-19) pandemic. Infections and fever often 
trigger seizures and status epilepticus in patients with DS, 
and recurrent respiratory infections are common8; hence, 
prophylaxis against infections and fever is needed in addition 
to antiseizure medications (ASMs).9 Patients need regular 
and frequent epilepsy specialist assessment and use of emer-
gency facilities is high.1,2,10
COVID-19 is an infectious respiratory disease caused 
by the most recently discovered SARS-CoV-2 coronavirus. 
Since the first recognized case in December 2019 in the 
city of Wuhan, China,9 COVID-19 transmitted rapidly and 
pandemic was declared by the World Health Organization 
(WHO) on March 11, 2020. Various degrees of social iso-
lation and physical distancing (“lockdown”) became manda-
tory from the first two weeks of March until around mid-May 
2020 mainly in the EU countries where we performed this 
study.
We aimed to explore the consequences of the COVID-19 
pandemic (including lockdown) on patients with DS and their 
families with respect to health and everyday life.
2 |  METHODS
We developed an online survey for caregivers of patients 
with DS divided into 6 sections exploring the following:
Section I on demographic information of the responder, 
section II on demographic information of the individual 
with Dravet syndrome, section III on the use of protective 
measures and contact before and during the containment/
quarantine, section IV on individual with DS and conta-
gion with COVID-19, section V on the symptoms related to 
DS before and during COVID-19 and organization of care, 
and section VI on the evaluation of future televisits and 
contacts. We summarized the survey in Table 1. Questions 
used checkboxes (multiple selections possible), dropdown 
lists (single selection only), or free text and were piloted by 
patient advocacy groups (PAGs) from Italy, Spain, France, 
and Croatia. Developed in English, survey versions were 
translated by local language-speaking PAG members into 
Spanish, French, German, Italian, Polish, Croatian, Dutch, 
and Serbian.
Invitations to participate were emailed to approxi-
mately 538 members of PAGs, mainly Dravet Syndrome 
Foundation Spain, Dravet Italia Onlus, Alliance Syndrome 
de Dravet (France), and Dravet Sindrom Hrvatska 
(Croatia), as well as through Internet-based social media 
(Facebook and Twitter). Survey was available from April 
14, to May 17, 2020 (1 month after onset of lockdown in 
EU and spanning the quarantine period). Answers were 
anonymous and did not include any data enabling the pa-
tient identification.
The ethics committee of Necker Enfants Malades univer-
sity hospital approved the study.
2.1 | Statistical analysis
For descriptive statistics, patients were stratified to four 
groups according to age at survey: preschool (<6 years), mid-
dle childhood (6-12 years, inclusive), adolescent (13-20 years, 
inclusive), and adults (≥21 years).
Both univariate and bivariate statistical analyses were per-
formed. Frequency tables and crosstabs were examined for 
potential associations between variables. Significance of as-
sociations was assessed by Pearson chi-square test (P < 0.05 
was regarded as significant).
Key Points
• We developed with European patient advocacy 
groups a survey to explore COVID-19 pandemics 
impact on individuals with Dravet syndrome
• Protection against infections in this population 
was highly used prior to COVID-19 and might 
have contributed in avoiding COVID19 infections
• Most individuals had stable epilepsy during lock-
down, however behavior disorders worsened in 
over one-third of patients
• Psychological remote support was available for 
few families although families expressed a clear 
need for such support
• Families are favourable for remote contact in pan-
demics and beyond for families travelling long 
distances to reach expert centres
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3 |  RESULTS
Two hundred and twenty-nine caregivers completed the sur-
vey. The patient cohort had 118 (52%) males.
Survey responses from 10 caregivers were excluded from 
the analysis since they lived in an area without mandatory 
lockdown. Mothers answered the survey in 75% of cases, 
fathers in 24%, and another family member in 1%. Median 
age at study entry of the 219 patients analyzed was 9 years 
10 months (range: 4 months to 49 years 4 months). Table 2 
shows additional patients data including age at DS diagnosis.
Seizures were reported based on seizures’ diaries. 
Forty-five responders (21%) declared the absence of 
seizures during the 3 months prior to lockdown. The re-
maining 174 responders (79%) declared seizures with 132 
patients having >2 seizures/month.
Prior to lockdown, patients with DS attended daily activ-
ities in either schools or special institutes (60.3% and 15.1%, 
respectively) or protected work and day centers activities 
(12.3% and 19.6%, respectively). During lockdown, 116 
(53%) families participated in didactic video conferences. 
These conferences were organized by either the team of the 
school/institute of their child (90% of cases) or by the fami-
lies support groups (10% of cases).
Regarding protection measures, 106 families (48%)  de-
clared that prior to COVID-19, and they were used to 
wear  similar or higher protections for their children. One 
hundred ninety-two (88%) responders declared that they 
modified the protection measures adapting them to the of-
ficial recommendation as for the face masks. The majority 
(81%) of the responders implemented decontamination when 
returning indoors (57% of them washing the exposed parts 
with soap and water; 26% having a shower and 17% by wash-
ing the exposed parts with hydro alcoholic solutions).
In comparison with the situation prior to COVID-19, 106 
responders (48%) declared that they used similar or high-
er-level protective measures against infections to those rec-
ommended against COVID-19 regarding individual isolation 
of individuals with DS and environment hygiene.. Restrictive 
attitudes prior to COVID-19 tended to correlate with individ-
uals with frequent febrile episodes (P = 0.029)—no correla-
tions were found with low/high frequency of seizures. During 
lockdown, 192 (88%) responders declared that they modified 
the protective measures based on official recommendations 
adding facemasks in more than half. Facemasks were mainly 
used for caregivers. The majority (81%) of responders im-
plemented also additional decontamination procedures when 
returning indoors. Decontamination procedures were used by 
100 families (81%) washing the uncovered parts with water 
and soap (57%) or with hydro alcoholic solutions (17%), and 
26% took showers every time they turned home from out-
side. All the family members used facemasks in half of cases 
(54%), the caregiver alone used them in 33% of cases, and 
T A B L E  1  Summary of the main questions of the survey (English 
version) detailing the different sections
Questions Answers
Section I: Demographic 
information of the responder
Answers Section I°
1.1 In which country do you live?
1.2 Region:
1.3 City:
1.4 Respondent to the survey: 1.4-a Mother
1.4-b Father
1.4-c Caregiver/other family 
member
1.4-d Tutor/educator (if 
patients are isolated in 
specialized centers)
Section II: Demographic 
information of the individual 
with Dravet Syndrome
Answers Section II
2.1 Gender: 2.1-a Male
2.1-b Female
2.2 Age: months/years
2.3 Age of diagnosis of DS: 
months/years
2.4 Prior to quarantine/isolation 




center for people with 
disabilities
2.4-c Work environment/day 
center
2.4-d Other (if other please 
specify)
2.5 Do you live in a country that 




Section III: Use protective 
measure /contact before 
and during the containment/
quarantine
Answers Section III
3.1 Did you use before COVID-
19 particular measures to protect 




3.2 How would you evaluate 
these measures compared 





3.2-d I do not know
3.3 Have you changed the 
means you used to protect the 
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Questions Answers
4.3 Did the individual with 
Dravet syndrome have fever 




4.4 If you answer yes to 4.3, 










4.6-4.14 (list of the symptoms 
reported at the time of the study 
for COVID-19 with Y/N




4.16 If you answer yes to 4.15, 




4.17 Was she/he hospitalized—
not just for COVID-19?
4.17-a Yes
4.17-b No
4.18 If you answer yes to 4.17, 
please answer the following: was 
she/he in intensive care?
4.18-a Yes
4.18-b No
Section V: Symptoms related to 
DS before and during COVID-
19 and organization of care
Answers Section V
5.1 In the previous three months 
before the pandemic, what was 














5.2 How can you describe the 





5.2-e Other (if other space for 
specify)




T A B L E  1  (Continued)
(Continues)
Questions Answers
3.4 Did you follow the 




3.5 If you answer yes to 3.4, 
please answer the following: 
who is wearing it?
3.5-a The patient with Dravet 
syndrome
3.5 b The caregiver
3.5-c Both, the patient and 
the caregiver
3.5-d Everybody in the family
3.6 Did you use specific 
decontamination measures 
for the family members of the 
individuals with Dravet when 




3.7 If you answer yes to 3.6, 
please answer the following: 
which measures did you use
3.7-a By washing the exposed 
parts with alcohol solutions
3.7-b By washing the 
exposed parts with soap and 
water
3.7-c By taking a shower
3.8 Have remote contact been 
organized by the institutions/
schools that the individual with 




3.9 If you answered no to 3.8, 
please answer the following: 
would you have liked to have 
a continuous contact with the 
educational team?





3.10 Have remote contacts been 
organized by the advocacy 
groups in your country?
3.10-a Yes
3.10-b Not at all
Section IV: Individual with DS 
and contagion with COVID-19
Answers Section IV
4.1 Has the individual with 
Dravet syndrome had contact* 




4.1-c I don't know
4.2 If you answer yes to 4.1, 
please answer the following: 
with whom?
4.2-a Other patients in the 
center or the rehabilitation 
site
4.2-b People providing care, 
rehabilitation or education 
(caregiver, doctor, nurse 
therapist, educator, etc)
4.2-c Family members
4.2-d Other (if other space  
for specify)
T A B L E  1  (Continued)
(Continues)
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Questions Answers
5.6 If you answer yes to 5.5, 
please answer the following: did 
they have the same availabilities 
as before?
5.6-a Better than usual
5.6-b As always
5.6-c Worse than usual
5.7 I If you answer yes to 5.5, 
please answer the following: 
how would you evaluate the 
waiting time to the consultation 
at the emergency room?
5.7-a Better than usual
5.7-b As always
5.7-c Worse than usual
5.8 Did you have a scheduled 
medical visit (consultation) with 
the specialist of the individual 




5.9 If you answer yes to 5.8, 
please answer the following: 
please check what applies best 
for this visit
5.9-a It was done onsite 
as planned with special 
permission
5.9-b It was done over the 
phone
5.9-c It was done via video 
conference
5.9-d It was postponed to a 
defined date
5.9-e It was postponed 
without a defined date
5.10 If it 5.9-d or 5.9-e “was 
postponed”, please answer the 
following: would you have like 
to have this visit through a video 
conference or a phone?
5.10-a Yes
5.10-b No
5.11 (this question was available 
just for the responders that 
answered to the previously 
“5.11” question) Why?
Free text
5.12 Have you had problems with 
the availability/reachability of 




5.13 If you answer yes to 5.12, 
please answer the following: was 
it resolved and how?
5.13-a There was a simple 
delay and drugs have 
already arrived
5.13-b The specialist had to 
intervene
5.13-c Other (if other space 
for specify)
5.14 Was the individual with 
Dravet syndrome participating 
in a clinical trial for Dravet 
syndrome/epilepsy-specific 
drugs during this lockdown?
5.14-a Yes
T A B L E  1  (Continued)
(Continues)
Questions Answers
5.15 How was this trial organized 
during this period? Choose what 
fits best the situation of the 
individual with DS
5.15-a Everything is being 
done as planned
5.15-b Visits were postponed 
and medication was sent 
home
5.15-c Visits were postponed 
and relative/caregiver had to 
go to the hospital to pick up 
the medication
5.15-d We had to exit 
definitely the trial
5.15-e Trial has been 
temporarily interrupted
5.16 Is the individual with Dravet 
syndrome participating in a 
clinical trial for COVID-19-




5.17 (If 5.16 Yes) Which one? free text
5.18 How would you evaluate 





5.18-e Other (if other space 
for specify)
5.19 Have you been offered 
remote psychological support 
for the individual with Dravet 




5.20 If you answer yes to 5.19, 
please answer the following: 




5.20-c Text (email, 
Whatsapp, sms...)
5.21 If you answer yes to 5.20, 
please answer the following: 
how much did you consider it 
useful?
5.21-a not at all useful
5.21-b Poorly useful
5.21-c Quite useful
5.21-d Very much useful
5.22 If you answer no to 5.19, 
please answer to the following: 




Section VI: Evaluation of future 
televisits and contacts
Answers Section VI°
6.1 Do you think that televisits 





6.1-d In case of emergency
6.1-e Other (precise)
T A B L E  1  (Continued)
(Continues)
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both the caregiver and the individual with DS in 11%. Only a 
few families used the facemask only for the individuals with 
DS (2%).
Only one patient in this series with respiratory symptoms 
and fever had a positive test to COVID-19, presenting fever 
but without exacerbation of seizures.
Contact with the reference medical team was possible 
in about half of patients. Of the 107 patients with clinic ap-
pointments previously scheduled for the period of lockdown, 
appointments were fulfilled onsite for 12 patients (11%), 
conducted remotely (phone/video call) for 39 (36%), and 
postponed for 56 (52%). Most of those with postponed ap-
pointments would have welcomed a phone/video call with 
their referring physicians during lockdown.
Over half of responders (53%) had confidence in remote 
contact and clinical evaluation and were supportive toward 
regular use of remote consultations, even post-COVID-19. 
Video was considered key for remote communications by 
55% of responders; 42% highlighted that video could be a 
quick and effective method of communication during such 
emergencies.
Most responders (58%) agreed that remote consultations 
could have advantages over regular ones, mainly in reduced 
travel and waiting rooms time. During lockdown, few fam-
ilies (9 families, 4%) needed emergency care that was ob-
tained as prior to pandemics.
Regarding seizures' frequency and behavior changes 
during lockdown, 14 responders answered “do not know” to 
if any changes occurred. Among the remaining 205 respond-
ers, seizures’ frequency was considered stable by most (79%), 
few reported an increase in seizure frequency (11%), and 10% 
perceived an improvement. Behavior changes were reported 
as worsened by 37%, stable in 57%, and improved in 6% of 
responders.
We found no significant correlation between the wors-
ening of the behavior and the age groups except for a trend 
with the adolescents group as behavior worsening was re-
ported in 32%, 39%, 42%, and 31% of the 4 age groups (pre-
school (<6 years), middle childhood (6-12 years, inclusive), 
adolescent (13-20 years, inclusive), and adults (≥21 years)), 
respectively.
Association between seizures’ frequency and behav-
ior changes was significant, with the majority of individu-
als reported with worsened epilepsy having also worsened 
behavior (91%) (P < 0.001) (Figure 1). However, behavior 
worsened also in 69% of patients with stable epilepsy and 
in 3% of patients with improved epilepsy. Furthermore, 11 
(27.5%) of the 40 patients who did not experience seizures 
during the 3 months prior and during the lockdown was re-
ported to have a behavior worsening (Figure 1).
Only 21 families (9.6%) reported receiving psychological 
support (12 from France, 6 from Spain, and 3 from Ex-EU re-
sponders). Four families received psychological support via 
email or short message service (SMS), 3 by video call, and 
14 by phone call. Half of families were unsatisfied with the 
psychological remote support. Out of 198 families (90.4%) 
Questions Answers
6.2 What would you prefer as a 






6.2-d other modes (precise)
6.3 Do you believe in the 
advantages of a televisit? 






6.4 Additional comments and/




T A B L E  1  (Continued)
T A B L E  2  Characteristics of patients: patients’ gender, the parent 


















Other EU 24 7%
Extra UE — —
Tot. 229 100%
DS clinical diagnosis (age) 54 29%
Before 1 y 150 68%
Within 3 y 51 23%
Between 3 and 10 y 18 8%
After 10 y — —
Tot. 229 100
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who were not offered psychological support, half stated that 
they would have welcomed it.
Twenty percent of responders (16 in Italy, 15 in Spain, 4 in 
France, 1 in Croatia, and 8 in other EU or Ex-EU) represented 
patients involved in clinical trials during lockdown. No pa-
tient had to stop the investigational treatments, and scheduled 
visits were postponed for 64% of them. Investigational treat-
ments were delivered at home or to institutions accessible to 
families and close to their homes.
4 |  DISCUSSION
Several studies have analyzed the burden of COVID-19 on 
patients with epilepsy11,12; we believe this is the first to 
study patients with DS and their families. Epilepsy was 
relatively stable during lockdown, while behavior disor-
ders worsened. Half of clinic appointments were post-
poned, and remote contact with families was variable. 
Families would have appreciated greater use of remote 
consultations with their medical teams. Remote consulta-
tions were largely considered a worthwhile future option 
for similar situations or routinely to decrease travel and 
waiting-room times.
Our data indicate that caregivers of patients with DS al-
ready use protective measures against transmission of infec-
tions; only one in five responders declared that they increased 
the protective measures during the COVID-19 pandemic. The 
main change was related to an increase use of facemasks use 
and decontamination procedures when coming back home. 
Facemasks were used by the whole family and by the care-
givers in the majority of cases. The individual with DS only 
in some of the cases was wearing a mask. This might be ex-
plained by the difficulty to have individuals with intellectual 
disability and behavior disorders to accept facemasks. The dif-
ficulty to keep the facemasks was an important issue for indi-
viduals with DS as this negatively impacted their community 
activities when it was available and their capacity to regain 
their institutions and schools. Prior to COVID-19, restriction 
and use of protective measures established by the families 
were higher in patients experiencing frequent febrile episodes. 
This was an expected result as the frequency of status epilepti-
cus induced by fever and febrile illness remains the major bur-
den in the patients’ group with frequent febrile episodes. This 
F I G U R E  1  Association between behavior changes and seizures’ frequency and between seizures frequency behavior changes. Pts, patients
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might explain the child care arrangement for children with DS 
with in many reports an impact on the parents carrier as they 
choose to avoid community child care modes at least in the 
first years of age were the febrile events and possible conse-
quent status and long lasting seizures are frequent.13
Behavior disorders worsened in over one-third of patients, 
in almost all children with worsened seizures’ frequency, but 
also with stable or improved seizures’ frequency. Despite a 
trend in correlation to the adolescents, there was no signifi-
cant relation with the different age groups and this worsening 
was reported in all 4 groups. Staying at home with additional 
time to rest/sleep and with fewer demanding activities might 
have been expected to improve behavior. Worsening in be-
havior might have been related to the lack of daily activi-
ties and rehabilitations programs for patients with DS during 
lockdown in addition to extreme isolation even in their famil-
iar nucleus. Emerging evidence on school or work-therapy 
activities suggests that patients with DS better managed epi-
lepsy and behavior when rehabilitative-educational support is 
constant. This might favor a better support of such activities 
against overprotection measures and isolation. This, however, 
should be balanced by the specific situation of each child and 
family helping to design the most adapted and personalized 
program. Finally, we did not detail in our survey the behav-
ior disorders’ subtypes but we focused only on the changes, 
so we cannot specify the most impacted underlying behavior 
disorders. Many families perceived psychosocial support as 
insufficient—only 21 of 219 families received such support. 
We speculate that phone or remote psychological support 
ought to be implemented to provide professional assistance to 
patients and caregivers. Indeed, telemedicine was generally 
perceived as supportive for patients and families. Although 
not the ideal medical solution and its usage varied across 
countries, telemedicine perhaps helped mitigate the isolation 
of patients and families. Protocols for telemedicine should be 
established in preparation for future similar situations, emer-
gency consultations, or in the case of the patient living far 
from the reference hospital.
Finally, we explored the effect of lockdown on partici-
pation in ongoing clinical trials. Reorganization of clinical 
trials seemed timely, since continuation of investigational 
treatments was preserved for all participants. To ensure both 
safety for patients and continuity of provision of drugs, the 
Food and Drug Administration (FDA)14 and the European 
Medicines Agency (EMA)15 advocated the use of telemed-
icine and virtual consultations during the COVID-19 pan-
demic. COVID-19 has perhaps accelerated a long-standing 
request from PAGs (patients’ advocacy groups) for the adop-
tion of emote consultations. Indeed, such televisits might be 
adopted for some of the routine visits. This would reduce 
travel times and their consequent physical and financial costs, 
ultimately improving the quality of life of both patients and 
caregivers.
5 |  CONCLUSIONS
Although the COVID-19 pandemic and lockdown presented 
difficulties for patients with DS and their families, prior 
adoption of protective measures against general infection 
might have contributed to avoiding high levels of contagion 
within this population. Lockdown restrictions did not change 
the epileptic condition of patients but worsened the behavior 
disorders. Structured protocols, regular remote consultations, 
online psychological support, and the possibility of emergency 
contacts with the medical teams—not only during special 
circumstances, but also as a settled system in addition to the 
classical in presence clinics—would be highly welcomed by 
the families of patients with DS. Patients’ advocacy groups 
could be valuable partners with physicians, regulatory 
agencies, and industries for the initiation, coordination, 
and implementation of specific protocols to be followed for 
clinical trials during future emergency situations or to help 
future patients and families friendly trials.
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